文献速递妇科

铂类双药方案的选择重要吗?评估铂类双药方案选择对铂敏感复发性卵巢癌后续PARP抑制剂及铂类耐药影响的研究

Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
PubMed 文献 · Gynecol Oncol · 2024-01-22

本研究回顾性纳入2015年1月1日至2022年1月1日接受铂类双药化疗后PARP抑制剂维持治疗的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者100例,比较卡铂+聚乙二醇脂质体多柔比星(CD)与其他铂类双药方案(OPDs)的肿瘤学结局。结果显示两组中位无进展生存期、至铂类耐药时间、总生存期及自PARP抑制剂起始的总生存期均无显著差异;作者认为使用CD似不加快PARP抑制剂或铂类耐药,但鉴于回顾性设计和小样本,需进一步研究。

要点

  • 100例铂敏感复发患者中25例接受CD、75例接受OPDs后行PARP抑制剂维持治疗。
  • CD组与OPDs组中位无进展生存期8个月对比7个月(p=0.26),无显著差异。
  • 自PARP抑制剂起始的中位总生存期CD组25个月对比OPDs组26个月(p=0.90)。

核心结论

  • 在铂敏感复发后PARP抑制剂维持治疗前使用含聚乙二醇脂质体多柔比星的铂类双药方案,与使用其他铂类双药方案相比,似不加快PARP抑制剂耐药或铂类耐药。
  • 接受非CD铂类双药方案者总生存期有增加的非显著趋势,但自PARP抑制剂起始的总生存期两组相似。
  • 鉴于本研究为回顾性设计且研究人群小,需进一步研究评估PARP抑制剂维持前铂类双药方案选择是否影响PARP抑制剂耐药、铂类耐药及生存。

研究设计与样本

  • 回顾性研究,纳入2015年1月1日至2022年1月1日接受铂类双药化疗后PARP抑制剂维持治疗的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者100例。
  • 比较接受卡铂+聚乙二醇脂质体多柔比星(CD)者与其他铂类双药方案(OPDs)者,采用描述性统计、Kaplan-Meier及单因素生存分析。

主要发现

  • 100例中25例(25%)接受CD,75例(75%)接受OPDs。
  • CD组与OPDs组中位无进展生存期分别为8个月与7个月(p=0.26)。
  • CD组与OPDs组中位至铂类耐药时间分别为15个月与13个月(p=0.54)。
  • CD组与OPDs组中位总生存期分别为64个月与90个月(p=0.28)。
  • CD组与OPDs组自PARP抑制剂起始的中位总生存期分别为25个月与26个月(p=0.90)。

临床怎么用

  • 作者认为,在铂敏感复发后PARP抑制剂维持治疗前使用含聚乙二醇脂质体多柔比星的铂类双药方案,与使用其他铂类双药方案相比,似不加快PARP抑制剂耐药或铂类耐药。

局限性

  • 本研究为回顾性研究。
  • 研究人群小。
  • 需进一步研究评估PARP抑制剂维持前铂类双药方案选择是否影响PARP抑制剂耐药、铂类耐药及生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The use of a platinum doublet for the treatment of platinum-sensitive epithelial ovarian cancer (EOC) recurrence is well established. The impact of the non‑platinum chemotherapy used as part of a platinum doublet on PARP inhibitor (PARPi) and platinum sensitivity it not known. We aimed to describe oncologic outcomes in cases of recurrent EOC receiving PARPi as maintenance therapy based on preceding platinum doublet. METHODS: Retrospective study of patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer treated with platinum doublet followed by maintenance PARPi from 1/1/2015 and 1/1/2022. Comparisons were made between patients receiving carboplatin + pegylated liposomal doxorubicin (CD) versus other platinum doublets (OPDs). Descriptive statistics, Kaplan-Meier and univariate survival analyses were performed. RESULTS: 100 patients received PARPi maintenance following a platinum doublet chemotherapy regimen for platinum-sensitive recurrence. 25/100 (25%) received CD and 75/100 (75%) received OPDs. Comparing CD and OPDs, median progression-free survival was 8 versus 7 months (p = 0.26), median time to platinum resistance was 15 versus 13 months (p = 0.54), median OS was 64 versus 90 months (p = 0.28), and median OS from starting PARPi was 25 versus 26 months (p = 0.90), respectively. CONCLUSIONS: Using pegylated liposomal doxorubicin as part of a platinum doublet preceding maintenance PARPi for platinum-sensitive recurrence does not seem to hasten PARPi resistance or platinum resistance compared to OPDs. Although there was a non-significant trend towards increased OS among patients who received a platinum doublet other than CD prior to PARPi, the OS from PARPi start was similar between groups. Given the retrospective nature of this study and small study population, further research is needed to evaluate if the choice of platinum doublet preceding PARPi maintenance impacts PARPi resistance, platinum resistance and survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Levine MD, Wang H, Sriram B, et al. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance. Gynecol Oncol. 2024. PMID: 38262238. doi:10.1016/j.ygyno.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。